pharma · Pulmonary Hypertension Associated with Interstitial Lung Disease · Pulmonary Arterial Hypertension
Insmed Incorporated
Insmed Limited
Insmed is a pharma organization headquartered in GB. Primary therapeutic focus areas include Pulmonary Hypertension Associated with Interstitial Lung Disease, Pulmonary Arterial Hypertension, Chronic Rhinosinusitis witho
Bridgewater Township, USA HQ
1,666 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Bridgewater Township, USA
- Employees
- 1,666
- Programs
- 7
- Drugs
- 18
- Patents
- 0
INS1009-212
Phase 3 · small molecule · Pulmonary Hypertension Associated with Interstitial Lung Disease
INS1009-212 for Pulmonary Hypertension Associated with Interstitial Lung Disease is a Phase 3 program (small_molecule) at Insmed Limited with 1 ClinicalTrials.gov record(s).
Internal code INS1009-212
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Insmed Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Pulmonary Hypertension Associated with Interstitial Lung Disease
- Status
- active
- Trials
- 1